French Validation of the Dual Diagnosis Screening Interview (F_DDSI)
F_DDSI
2 other identifiers
observational
210
1 country
2
Brief Summary
In France, there are no tools for screening psychiatric comorbidities for individuals with Substance Use Disorders. The literature shows that the cooccurrence of these psychiatric disorders in the same individual is frequent. It negatively impacts the healing prognosis, complicates the diagnostic processes and the type of care to be introduced for patients. The creation of reliable, fast and easy-to-use tools for caregivers and researchers is therefore necessary to improve quantitatively and qualitatively the care of patients. There is a Spanish scale that meets these criteria, the Dual Diagnostic Screening Interview (S\_DDSI). The main objective of this study is to validate the DDSI in French. The secondary objectives are the evaluation of the psychometric qualities of F\_DDSI (French version) and adaptation of this scale into an application for Android and iOS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 14, 2018
CompletedFirst Submitted
Initial submission to the registry
June 28, 2018
CompletedFirst Posted
Study publicly available on registry
July 13, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2019
CompletedJuly 13, 2018
June 1, 2018
11 months
June 28, 2018
July 12, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The response rates for each of the item composing the instrument
From March 14, 2017 to June 2019
Psychometric qualities of the new scale
Sensitivity, specificity, and the positive and negative predictive values for each disorder measured by the DDSI will be calculated in comparison with the MINI
From March 14, 2017 to June 2019
Study Arms (2)
Pre-test group
Patients from CMP B coming for consultation or day hospital
Test group
Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
Interventions
Eligibility Criteria
Both female and male participants of 18 years old and more are being studied.
You may qualify if:
- Phase 2 : Patients coming for consultation in the department or day hospital Phase 3: Subjects presenting for one or more substances a diagnosis of Substance Use Disorders (SUD) according to the DSMV criteria.
You may not qualify if:
- Phase 2
- Subject who do not understand French
- Subject unable to answer questions cognitively
- Phase 3
- Subject who do not understand French
- Subject unable to answer questions cognitively
- Subjects with a mental disorder of the axis I of the DSMIV not stabilized making impossible the filling of the questionnaire (in particular acute states delusional and dissociative)
- Subjects who participated in the pre-test phase (2)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, 63003, France
CH Etienne Clémentel
Enval, Auvergne, 63530, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Georges BROUSSE, PhD
University Hospital, Clermont-Ferrand
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 28, 2018
First Posted
July 13, 2018
Study Start
March 14, 2018
Primary Completion
January 31, 2019
Study Completion
June 30, 2019
Last Updated
July 13, 2018
Record last verified: 2018-06